TuHURA Biosciences (NASDAQ:HURA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a report released on Sunday.

A number of other research analysts have also weighed in on HURA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Maxim Group dropped their price objective on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $10.33.

TuHURA Biosciences Trading Down 4.9%

HURA stock opened at $0.92 on Friday. TuHURA Biosciences has a 1-year low of $0.90 and a 1-year high of $5.50. The firm has a market cap of $46.96 million, a PE ratio of -1.83 and a beta of -0.03. The business’s 50-day moving average price is $2.08 and its two-hundred day moving average price is $2.43.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in TuHURA Biosciences in the third quarter valued at $26,000. JPMorgan Chase & Co. bought a new position in shares of TuHURA Biosciences in the 2nd quarter valued at about $27,000. Intech Investment Management LLC acquired a new stake in shares of TuHURA Biosciences in the second quarter valued at about $29,000. Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences in the second quarter valued at about $30,000. Finally, Merck & Co. Inc. bought a new stake in TuHURA Biosciences during the second quarter worth about $31,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.